Author

A. Kukuljac

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:virus· 1

Frequent Co-Authors

C. Ma· 1 shared D. Schultz· 1 shared F. Zhang· 1 shared J. Townsend· 1 shared J. Wang· 1 shared M. D. Sacco· 1 shared M. Marty· 1 shared N. Kitamura· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

C. Ma

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity

N. Kitamura, M. D. Sacco, C. Ma, Y. Hu, J. Townsend, X. Meng, F. Zhang, X. Zhang, A. Kukuljac, M. Marty, D. Schultz, S. Cherry, Y. Xiang, Y. Chen, J. Wang

This study designs non-covalent SARS-CoV-2 Mpro inhibitors using structure-based design and Ugi-4CR reactions, identifying 23R as the most potent compound with antiviral activity.

bioRxiv · Dec 19, 2020 · PreprintPharmacology & Toxicology